By Olivia Bugault

Novartis AG said Monday that the phase 3 of its Ruxcovid study didn't meet its primary endpoint of reducing the number of hospitalized Covid-19 patients with complications.

Data show that ruxolitinib medicine, on top of standard of care therapy, didn't significantly reduce the number of Covid-19 patients in hospital who experienced severe complications including death, respiratory failure requiring mechanical ventilation or admission to the intensive care unit, the pharmaceutical giant said.

"The trial also did not show clinically relevant benefit among secondary and exploratory endpoints including mortality rate by day 29, and time to recovery," Novartis said.

Write to Olivia Bugault at olivia.bugault@wsj.com

(END) Dow Jones Newswires

December 14, 2020 01:52 ET (06:52 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Novartis Charts.
Novartis (NYSE:NVS)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Novartis Charts.